Changeflow GovPing Pharma & Drug Safety Patent Application for Biodegradable Particles ...
Routine Notice Added Draft

Patent Application for Biodegradable Particles Delivering Therapeutic Agents

Email

Summary

The USPTO has published a new patent application (US20260083830A1) for biodegradable polymeric particles designed for the extended, controlled release of positively charged therapeutic agents at neutral pH. The application details microparticles and nanoparticles comprising an uncapped polymer matrix and a net positively charged therapeutic agent.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a publication of a patent application filed with the USPTO, specifically application US20260083830A1. It describes biodegradable microparticles and nanoparticles made from polymers like PLGA or PLA, designed to deliver positively charged therapeutic agents, such as proteins or peptides, with extended and controlled release at neutral pH. The application also covers methods for making and administering these particles.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it represents potential future intellectual property in the field of drug delivery systems. Companies involved in pharmaceutical development, particularly those working with protein or peptide therapeutics and advanced delivery mechanisms, should be aware of this filing for competitive intelligence and potential licensing opportunities.

Archived snapshot

Mar 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

BIODEGRADABLE POLYMERIC PARTICLES FOR DELIVERY OF POSITIVELY CHARGED THERAPEUTIC AGENTS

Application US20260083830A1 Kind: A1 Mar 26, 2026

Inventors

Steven Paul Schwendeman, James Moon, Corrine Din

Abstract

The disclosure relates to microparticles and nanoparticles comprising a polymer matrix comprising an uncapped polymer and a net positively charged therapeutic agent at neutral pH. More particularly the disclosure relates to PLGA and/or PLA particles comprising an uncapped polymer for extended, controlled release of positively charged proteins or peptides at neutral pH. Methods of making the particles and administering the particles are also provided.

CPC Classifications

A61K 39/0008 A61K 9/1647 A61K 9/1694 A61P 37/06 A61K 2039/6093 A61K 2039/627

Filing Date

2023-09-06

Application No.

19109261

View original document →

Named provisions

Abstract Inventors CPC Classifications

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260083830A1

Who this affects

Applies to
Drug manufacturers Medical device makers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing
Activity scope
Drug Delivery Systems
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Medical Devices Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!